Skip to content

REMEDENT, INC.

CIK 0001078037

← back to feed
Revenue (TTM)
$1.14M
−33.6% YoY Q3 Feb 2021
Net Income (TTM)
−$48.95K
−140.3% YoY Q3 Feb 2021
EPS Diluted (TTM)
−$0.02
−136.4% YoY Q3 Feb 2021
Gross Margin
64.7%
Q3 Feb 2021
Operating Margin
-3.2%
Q3 Feb 2021
Net Margin
-4.3%
Q3 Feb 2021
Free Cash Flow (TTM)
—
Q3 Feb 2021
Cash
$83.3K
Q3 Feb 2021
Total Debt
$1.14M
Q3 Feb 2021
Shares Outstanding
20M sh
Q3 Feb 2021

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings